MedWatch

FDA approves Lundbeck's schizophrenia treatment for teenagers

Following the green light from US health authorities, schizophrenia treatment Rexulti may now be used in patients as young as 13 years in the US.

Photo: Thomas Borberg

On Thursday, Lundbeck and partner Otsuk received the green light from the US Food and Drug Administration (FDA) to expand the use of the schizophrenia treatment to include patients aged 13 to 17 years, reports a shared press release.

Up to now, Rexulti has only been approved to treat adults with schizophrenia and as an adjunctive treatment of major depressive disorder. However, the younger segment is particularly important when it comes to schizophrenia, as the disorder often starts developing in adolescence.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs